Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Autonomous Technology & Robotics ETF vs Becton Dickinson and Co — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $123.27, while Becton Dickinson and Co trades at $151.94 (market cap $41.87B). The key difference: Becton Dickinson and Co pays a 2.76% dividend while ARK Autonomous Technology & Robotics ETF pays none, and ARK Autonomous Technology & Robotics ETF is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| ARKQ | BDX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $185.39 |
52-Week Low | $91.86 | $135.49 |
Market Cap | — | $41.87B |
Enterprise Value | — | $58.33B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $123.99, down 0.57% with a bearish technical signal from moving averages. The ETF focuses on autonomous technology and robotics, benefiting from AI momentum with 57% gains since Q1 2026. Support levels cluster around $122-124 while resistance sits at $126-128. Recent news highlights China's EV targets and humanoid robotics growth projections reaching $200 billion by 2035.
The ETF shows strong momentum in AI and robotics themes but carries premium valuations with a 36x P/E ratio. Key risks include sector concentration and dependency on technological adoption rates. Institutional interest remains strong with $2.7 billion in assets, though technical indicators suggest near-term consolidation pressure.
BDX trades at $151.94, up 0.72% on the day, with a bearish technical signal despite recent earnings beats. The stock is supported by consistent revenue growth, reaching $21.84B in 2025, and a forward P/E of 26.52. Analyst consensus is mixed with a $173.40 price target, and the company maintains a solid dividend, recently paying $1.05 per share. Cash flow trends show variability, with 2025 net cash flow negative $1.00B, though 2026 projects a positive $346M.
The outlook for BDX balances strong fundamentals against near-term headwinds. Revenue growth and strategic positioning in medical technology offer upside, but investor sentiment is cautious due to bearish technicals and margin pressures. Risks include hospital spending caution and competitive dynamics. The stock presents a hold case for long-term investors, with potential catalysts from continued earnings outperformance and innovation in healthcare technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
